SCHEMBL22004159

SCHEMBL22004159

CC(C)n1c(-c2cncnc2)cc2cc(C(F)(F)F)ccc21

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACLY P53396 3/20 0.48
ALDH1A1 P00352 1/20 0.42
CYP11B2 P19099 4/20 0.37
CYP11B1 P15538 3/20 0.37
HTR2B P41595 1/20 0.35
HTR6 P50406 1/20 0.35
USP2 O75604 1/20 0.33
HTT P42858 1/20 0.33
NCOA1 Q15788 1/20 0.33
NCOA3 Q9Y6Q9 1/20 0.33
FYN P06241 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP3A5 P20815 1/20 0.33
ABL1 P00519 1/20 0.32
CYP19A1 P11511 1/20 0.32
PKM P14618 1/20 0.32
NR1I2 O75469 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2B Q13224 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22004160 0.82 ACLY (0.51) ACLYALDH1A1CYP11B2CYP11B1HTR2B
SCHEMBL22005105 0.81 ACLY (0.46) ACLYALDH1A1CYP11B2CYP11B1USP2
SCHEMBL22004122 0.80 ACLY (0.46) ACLYCYP11B2CYP11B1USP2HTT
SCHEMBL22005030 0.77 ACLY (0.40) ACLYALDH1A1CYP11B2CYP11B1USP2
SCHEMBL22004392 0.76 ACLY (0.47) ACLYALDH1A1CYP11B2CYP11B1CYP19A1
SCHEMBL22004330 0.72 ACLY (0.50) ACLY
SCHEMBL21304004 0.67 ALDH1A1 (0.55) ALDH1A1PKM
SCHEMBL12377318 0.66 CACNA1D (0.50) ALDH1A1CYP3A4PKM
SCHEMBL355696 0.66 USP2 (0.47) ALDH1A1CYP11B2CYP11B1HTR2BHTR6
SCHEMBL12377327 0.65 ALDH1A1 (0.47) ALDH1A1USP2CYP3A4PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200157076-A1 ACLY INHIBITORS AND USES THEREOF NIMBUS DISCOVERY, INC. 2020-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200157076-A1 ACLY INHIBITORS AND USES THEREOF ACLY, ATP5ME, ATP5MG ACLY 1/4885ALDH1A1 1455/4885CYP11B2 2971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.